TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35189843
Drug: Tablet-based video
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based video intervention about IPV and safety behaviours
Study: 35667527
Drug: Stereotactic ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic ablative radiotherapy (SABR) planned for 332 lesions in 296 separate PTVs, with common prescriptions of 30-35 Gy in 5 fractions (43% of lesions) and 20-24 Gy in 1 fraction (33% of lesions).
Study: 33528816
Drug: Multi-period design
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-period design with varying weekly measurement schemes
Study: 33908117
Drug: Placebo (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.2 mL of placebo)
Study: 33691699
Drug: Stepwise CMD
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepwise CMD risk assessment and individualized treatment
Study: 34273987
Drug: Intravenous LPS
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous LPS (Escherichia coli O113, 2 ng/kg)
Study: 36469573
Drug: Neoadjuvant durvalumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant durvalumab plus tremelimumab (combination therapy)
Study: 34118298
Drug: Delgocitinib 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delgocitinib 0.25% ointment
Study: 34118298
Drug: Delgocitinib 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delgocitinib 0.25% or 0.5% ointment (Part 2)
Study: 32947424
Drug: Pregnenolone adjunct
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnenolone adjunct to risperidone
Study: 32947424
Drug: Placebo adjunct
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo adjunct to risperidone
Study: 35346889
Drug: Maternal glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal glycemic control (fasting and 1-hour postprandial or serial intrapartum capillary blood glucose screening with insulin treatment as indicated)
Study: 33741732
Drug: Camrelizumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab (3 mg/kg, once every 2 weeks) plus apatinib (500 mg, once per day)
Study: 33359589
Drug: Daily dosing
Normalized name: Osmolex 322 MG Daily Dosing Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing of PTAH (cohorts 1 and 3A)
Study: 32987448
Drug: Mupirocin ointment
Normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin ointment
Study: 33495008
Drug: GH 4
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 3 MCG/0.2 ML Injectable Suspension, 6m through 4y (EUA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 4 IU/day subcutaneous injection
Study: 34602396
Drug: Intravenous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthesia with dexmedetomidine and propofol combined with seaweed polysaccharides
Study: 34602396
Drug: Intravenous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthesia with sufentanil combined with propofol
Study: 34958402
Drug: Medication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication therapy for osteoporosis
Study: 33198942
Drug: Passive Scattering
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive Scattering Proton Therapy (PSPT)
Study: 34259871
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of smoking cessation medication
Study: 34340163
Drug: Early physical
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early physical therapy (PT) treatment including exercise instructions from the first postoperative day
Study: 32383985
Drug: Quetiapine augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine augmentation
Study: 33411115
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment with epoetin beta pegol targeting hemoglobin level of 11 g/dL or higher
Study: 37316163
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg)
Study: 35175011
Drug: In-office bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-office bleaching with PNF desensitizing gel (Desensibilize KF 2%) applied for 10 min before each session
Study: 34088270
Drug: SPI-guided analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPI-guided analgesia (fentanyl boluses of 1.0 µg/kg to maintain SPI value between 20 and 50)
Study: 34524022
Drug: Fast-acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-acting insulin aspart (FiAsp)
Study: 36010630
Drug: PEA‐LUT therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEA‐LUT therapy
Study: 36315189
Drug: Automated insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated insulin dosing (AID)
Study: 33433644
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg ASP8062
Study: 33433644
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg ASP8062
Study: 34699549
Drug: Heparin ±
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin ± GPIs
Study: 39565980
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment alone (control group)
Study: 34839672
Drug: Immunonutrient-enriched supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunonutrient-enriched supplement for 7 days
Study: 34839672
Drug: Standard high-protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard high-protein normocaloric supplement (control) for 7 days
Study: 35496724
Drug: Multimodal chiropractic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal chiropractic treatment including spinal manipulation
Study: 35496724
Drug: Multimodal chiropractic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal chiropractic treatment including spinal manipulation, together with podiatric custom-made orthoses
Study: 32087126
Drug: Emollient group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emollient group (Diprobase cream or DoubleBase gel) with standard skin-care advice
Study: 34547217
Drug: Botulinum neurotoxin
Normalized name: Botulinum neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum neurotoxin A therapy (BoNT‐A) with intensive rehabilitation
Study: 32321717
Drug: Taxane treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane treatment (docetaxel)
Study: 34915104
Drug: Prebiotic (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic (16 g inulin)
Study: 34915104
Drug: Control (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (16 g maltodextrin)
Study: 35783144
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (10 min of evaluation and warm-up, 40 min of therapist-directed exercise therapy, and 10 min of relaxation, three times per week for 12 weeks)
Study: 33060506
Drug: Insulin-dependent diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-dependent diabetes
Study: 34711060
Drug: Jet injection
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet injection with a slot-shaped nozzle
Study: 34711060
Drug: Jet injection
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet injection with differently shaped nozzles
Study: 35833889
Drug: Germinated brown
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Germinated brown rice (GBR), 100 g per day for 12 weeks
Study: 32648022
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg NZBC extract prior to a high-carbohydrate, high-fat liquid meal (n=12)
Study: 32648022
Drug: 8-days supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-days supplementation with NZBC extract (600 mg day-1) (n=13)
Study: 33399381
Drug: Generic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic preparation of ropivacaine
Study: 37952132
Drug: Aspirin 81
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 mg daily
Study: 34203286
Drug: Combined Creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Creatine and Sodium Bicarbonate (CSB) supplementation (20 g/day creatine and 0.3 g/kg/day sodium bicarbonate, taken four times a day for seven days)
Study: 33851329
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg Cr(VI)
Study: 35871058
Drug: EPA-E 2.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA-E 2.7 g/day
Study: 33298604
Drug: Propofol Target-Controlled
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol Target-Controlled Infusion (TCI)
Study: 33130104
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g gluten/d for 14 days
Study: 33130104
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g gluten/d for 14 days
Study: 35800292
Drug: Denosumab (DB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (DB group; 120 mg once every 4 weeks with loading doses of 120 mg on days 8 and 15; n = 80)
Study: 35800292
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZA group; 4 mg once every 4 weeks; n = 80)
Study: 32993338
Drug: Corticosteroid (CS)
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (CS) in periarticular injection
Study: 32993338
Drug: No corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No corticosteroid (no-CS) in periarticular injection
Study: 36192738
Drug: Home stretching
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home stretching exercises with spinal manipulative therapy
Study: 34371883
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus BHC (berberine, hesperidin, and chromium picolinate)
Study: 34371883
Drug: Metformin only
Normalized name: Metformin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin only (control group)
Study: 35027477
Drug: Intrathecal 2-chloroprocaine
Normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal 2-chloroprocaine 1% (27.8 mg estimated ED90 in cohort I, 28 mg fixed dose in cohort II)
Study: 32678299
Drug: Foot and
Normalized name: Carrington Foot and Body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot and back massage (6 sessions of 30 min, twice weekly for 3 weeks)
Study: 35340044
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with potent topical corticosteroid (TCS) and handheld narrowband ultraviolet B
Study: 32418143
Drug: Co‐Plavix® (fixed‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co‐Plavix® (fixed‐dose combination of 100 mg acetylsalicylic acid and 75 mg clopidogrel)
Study: 32418143
Drug: Reference formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulations (coadministration of individual formulations of 100 mg acetylsalicylic acid and 75 mg clopidogrel)
Study: 36174958
Drug: Phase 2
Normalized name: Premphase 28 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 2 trial with randomized evaluation of multiple doses
Study: 36174958
Drug: Phase 3
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase 3 trial with selected dose
Study: 34488824
Drug: Verum acupuncture
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum acupuncture (1-hour sessions, twice a week for 12 weeks)
Study: 36062831
Drug: EMDR treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMDR treatment (weekly for 3 to 9 months)
Study: 32753339
Drug: COSMOS intervention
Normalized name: Cosmos sulphureus flowering top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: COSMOS intervention (Communication, Systematic pain management, Medication reviews, Organization of activities, Safety)
Study: 38600496
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (CC)
Study: 32889413
Drug: Individualized goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized goal-directed therapy (GDT)
Study: 32557506
Drug: 2× PPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2× PPI (Pantoprazole 40 mg 2×/day)
Study: 32557506
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (after PPI therapy)
Study: 36414172
Drug: PRP injection
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP injection following arthrocentesis
Study: 32880220
Drug: Transdermal 17β‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17β‐estradiol (50 µg/day) with progesterone (200 mg/day for 12 days/month)
Study: 32665311
Drug: Buparlisib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib (80 mg) plus carboplatin (AUC=5 every 3 weeks)
Study: 32665311
Drug: Buparlisib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib (60 mg) plus lomustine (100 mg/m2 every 6 weeks)
Study: 32665311
Drug: Buparlisib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib (80 mg or 100 mg) plus carboplatin or buparlisib (60 mg) plus lomustine
Study: 35636766
Drug: No preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preparation (NMBP)
Study: 32248638
Drug: Biobehavioral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biobehavioral intervention (12 weekly, 30-minute telehealth sessions)
Study: 33642330
Drug: DEX (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX (intravenous injection; 0.5 μg/kg)
Study: 33642330
Drug: LID (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LID (1.5 mg/kg)
Study: 33642330
Drug: PBO (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBO (10 mL normal saline)
Study: 35794623
Drug: Nintedanib 150
Normalized name: nintedanib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 150 mg bid
Study: 34077602
Drug: Combined self‐management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined self‐management and exercise programme (treatment group)
Study: 35690997
Drug: Control vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vehicle lotion
Study: 32073177
Drug: MDMA (75-125
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (75-125 mg)
Study: 34083744
Drug: Extended-release naltrexone/bupropion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone/bupropion (NB)
Study: 34259193
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (SQT): esomeprazole 20 mg twice daily for 10 days, amoxicillin 1000 mg twice daily for 5 days, clarithromycin 500 mg and tinidazole 500 mg twice daily for 5 days
Study: 33115428
Drug: Pharmacogenetic testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenetic testing (PGx) for antidepressant prescribing
Study: 35045208
Drug: LC51‐0255 (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC51‐0255 (0.25, 0.5, 1, 2, or 4 mg)
Study: 35172273
Drug: StemPrintER Risk
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: StemPrintER Risk Score (SPRS) with Clinical Treatment Score (CTS)
Study: 35172273
Drug: Oncotype DX
Normalized name: brompheniramine maleate / dextromethorphan hydrobromide / pseudoephedrine hydrochloride Oral Solution [Myphetane DX]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oncotype DX Recurrence Score (RS) with Clinical Treatment Score (CTS)
Study: 35172273
Drug: StemPrintER Risk
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: StemPrintER Risk Score (SPRS) in node-negative patients with Clinical Treatment Score (CTS)
Study: 35373443
Drug: Low-Dose-Rate Brachytherapy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Dose-Rate Brachytherapy (BT)
Study: 33865239
Drug: Intermediate-dose prophylactic
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose prophylactic anticoagulation
Study: 32992075
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for atorvastatin
Study: 33865239
Drug: Standard-dose prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose prophylactic anticoagulation
Study: 35585641
Drug: Standard schizonticidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard schizonticidal treatment plus 7-day high dose primaquine (total dose 7mg/kg)
Study: 36436076
Drug: Costoclavicular brachial
Normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Costoclavicular brachial plexus block (CC group)
Study: 35405965
Drug: Green mandarin
Normalized name: mandarin oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green mandarin extract (PTE) 300 mg/day for 12 weeks
Study: 34229149
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen
Study: 34034400
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment with suplatast tosilate.
Study: 33114364
Drug: WS group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: WS group 1 (500 mL purified water)
Study: 33114364
Drug: WS group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: WS group 2 (200 mL purified water)
Study: 33114364
Drug: WS group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: WS group 3 (100 mL purified water)
Study: 32078484
Drug: LDL cholesterol
Normalized name: LDL cholesterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL cholesterol <70 mg/dL
Study: 32078484
Drug: LDL cholesterol
Normalized name: LDL cholesterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL cholesterol 100±10 mg/dL (90-110 mg/dL)
Study: 32933153
Drug: Krill Oil
Normalized name: Krill oil
DrugBank: Krill oil (DB16615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krill Oil (KO) 1.27 g/day of long-chain omega-3 PUFA (0.76 g EPA, 0.42 g DHA)
Study: 32933153
Drug: Fish Oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish Oil (FO) 1.44 g/day of long-chain omega-3 PUFA (0.79 g EPA, 0.47 g DHA)
Study: 35932394
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard smoking cessation treatment)
Study: 37482564
Drug: Abrocitinib 100
Normalized name: abrocitinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrocitinib 100 mg once daily
Study: 34897593
Drug: Zhuang medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhuang medicine medicated thread moxibustion (ZMTM) combined with Western medicines
Study: 34897593
Drug: Western medicines
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicines alone (pidotimod dispersible tablets, vitamin B compound tablets, compound cod liver oil‐zinc oxide ointment)
Study: 34897593
Drug: ZMTM combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZMTM combined with Western medicines
Study: 34967864
Drug: tSVF injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: tSVF injection in the lateral 5 cm of the horizontal scar of 1 breast
Study: 34967864
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection in the contralateral breast
Study: 35591203
Drug: Balance and
Normalized name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [Sunsolve MD Balance and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance and coordination training with vibrotactile sensory augmentation (SA)
Study: 35591203
Drug: Balance and
Normalized name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [Sunsolve MD Balance and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance and coordination training without vibrotactile sensory augmentation (SA)
Study: 34493431
Drug: TAS-115 600
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-115 600 mg/d
Study: 34493431
Drug: TAS-115 400
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-115 400 mg/d
Study: 36394838
Drug: DCVax-L plus
Normalized name: DCVax-L
DrugBank: DCVax-L (DB17580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCVax-L plus SOC temozolomide
Study: 33965626
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of antenatal corticosteroids (ACS)
Study: 33965626
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of antenatal corticosteroids (ACS)
Study: 36215414
Drug: Alfentanil 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 20 μg/kg ideal bodyweight
Study: 33350678
Drug: Second-line therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line therapy (37% of patients received this treatment)
Study: 33350678
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no second-line therapy)
Study: 37035316
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment (SMT)
Study: 33810451
Drug: >Your< Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: >Your< Iron Syrup
Study: 35411147
Drug: Intravenous glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous glutamine (0.5 g/kg of 20% glutamine solution diluted with 0.9% NaCl up to 500 mL over 24 hours)